Retatrutide: What the Research Actually Shows
A triple GIP, GLP-1, and glucagon receptor agonist that has produced some of the largest weight-loss figures ever reported in a phase 3 obesity trial, with published, peer-reviewed phase 3 results in both obesity and type 2 diabetes. It remains investigational and not FDA-approved while long-term data accumulate.
A Triple Receptor Agonist, Not Just Another GLP-1
Retatrutide is a synthetic peptide and triple receptor agonist, it activates the GIP, GLP-1, and glucagon receptors simultaneously. It's Eli Lilly's investigational compound (LY3437943), currently in Phase 3 trials, not an approved drug. Mechanistically, it's a direct extension of the same GIP/GLP-1 signaling family as semaglutide and tirzepatide already on this site, retatrutide adds glucagon receptor agonism on top, which is thought to add direct energy-expenditure and hepatic fat-metabolism effects beyond the appetite and insulin-sensitivity effects GLP-1/GIP agonism already provides.
Evidence Summary
Mechanism, Diabetes Trial, and Obesity Trial, Graded Separately
Mechanism
Li W, Zhou Q, Cong Z, et al. "Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide." Cell Discovery. 2024 Jul 17;10:77. doi: 10.1038/s41421-024-00700-0. Cryo-EM structures of retatrutide bound to all three receptors, resolved to 2.68-3.26 Å. The paper shows how the molecule maintains contact with conserved residues shared across the three receptors while also accommodating receptor-specific differences, particularly a loop region (ECL1) that's rigid in two of the three receptors but flexible in the third, structural biology, not a clinical outcome, but a solid, independently-reviewed mechanistic basis for how one molecule can activate three different receptors at once.
Structural Biology (Cryo-EM) · Endpoint: Mechanism OnlyType 2 Diabetes, Published RCT
Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet. 2026;407:2402-13. doi: 10.1016/S0140-6736(26)00967-0. PMID: 42250575. ClinicalTrials.gov: NCT06354660. 537 adults with type 2 diabetes (baseline A1c 7.0-9.5%), 40-week randomized, double-blind, placebo-controlled design. A1c fell 1.69% (4 mg), 1.86% (9 mg), and 1.94% (12 mg) from baseline, a 1.12 percentage-point difference versus placebo at the highest dose (95% CI -1.39 to -0.85, P<.0001). Body weight fell 11.5% (4 mg) to 15.3% (12 mg), roughly 15.1 kg at the highest dose. This is real, published, peer-reviewed randomized trial data, the strongest evidence tier on this page.
Phase 3 RCT, Peer-Reviewed & Published · Endpoint: A1c & Body Weight, T2D PopulationObesity, Published RCT
Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y; TRIUMPH-1 Investigators. "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." New England Journal of Medicine. Published online September 29, 2026. doi: 10.1056/NEJMoa2604169. PMID: 42814954. ClinicalTrials.gov: NCT05929066. 2,339 adults with obesity and without diabetes, randomized to once-weekly retatrutide (4 mg, 9 mg, or 12 mg) or placebo for 80 weeks, double-blind. The trial's main analysis counts everyone who was randomized, whether or not they stayed on the drug (the treatment-regimen estimand). On that basis, average weight change at 80 weeks was -17.6% (4 mg), -23.7% (9 mg), and -25.0% (12 mg), versus -3.9% with placebo. Lilly's topline report also gave the efficacy estimand, which estimates the effect if everyone had stayed on treatment: -19.0%, -25.9%, and -28.3%, versus -2.2% with placebo. Retatrutide also reduced knee osteoarthritis pain and sleep apnea events in the subgroups who had those conditions. Stomach and bowel side effects were the most common. This is published, peer-reviewed randomized trial data, though it is sponsored by Lilly and runs 80 weeks.
Phase 3 RCT, Peer-Reviewed & Published · Endpoint: Body Weight at 80 Weeks, Obesity PopulationWhat's Established, and What's Still Outstanding
Taken together, the human data on retatrutide is among the strongest ever assembled for an obesity pharmacotherapy at this stage of development: published phase 3 randomized trials in both type 2 diabetes and obesity, with average weight loss of 25 percent at the highest dose counting everyone randomized, and about 28 percent in the estimate for people who stay on treatment. That is a genuinely strong position. Three things still need to land before the picture can be called settled.
Long-term data beyond 80 weeks, on both efficacy durability and safety, is still limited. The published trials are industry-sponsored (Lilly); independent, non-sponsor replication hasn't been published. And retatrutide's specific added value over tirzepatide, the practical question most people considering it actually have, hasn't been tested in a published head-to-head trial. A direct comparison (TRIUMPH-5) is underway, but until it reports, the comparison rests on cross-trial numbers, not a randomized comparison of the two drugs against each other. Lilly has said it plans to apply for FDA approval in the first quarter of 2027.
Investigational, not FDA-approved for any indication.
How This Fits the Cellular Medicine Framework
Retatrutide sits at the same entry point as every hormone and peptide on this site, cell signaling, but through three receptors instead of one. GIP, GLP-1, and glucagon receptor agonism converge on downstream changes in cellular metabolism (glucose and fatty acid handling) and, the mechanistic hypothesis behind the added glucagon-receptor effect, direct changes in hepatic and adipose energy expenditure beyond what appetite suppression alone would produce.
References
- Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. doi:10.1038/s41421-024-00700-0
- Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407:2402-13. doi:10.1016/S0140-6736(26)00967-0 · PMID: 42250575 · NCT06354660
- Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169 · PMID: 42814954 · NCT05929066
Related Reading
Tirzepatide: The approved dual agonist retatrutide is being measured against.
Semaglutide: The most widely studied weekly GLP-1, and the usual yardstick newer weight-loss drugs are compared with.
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.